Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration

Authors

• Victoria Navarro-Compán
• John D Reveille
• Proton Rahman
• José A Maldonado-Cocco
• Marina Magrey
• Rebecca Bolce
• Tommaso Panni
• Andris Kronbergs
• Martin Rudwaleit

Language

English

Publication Date

9-1-2025

Journal

Advances in Therapy

DOI

10.1007/s12325-025-03305-5

PMID

40694276

PMCID

PMC12394305

PubMedCentral® Posted Date

7-22-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Introduction: The objective of this study was to assess treatment response to ixekizumab, an interleukin-17A antagonist, by shorter versus longer symptom duration (< 5 years vs. ≥ 5 years) in patients with radiographic axial spondyloarthritis (r-axSpA) and non-radiographic axial spondyloarthritis (nr-axSpA) up to 52 weeks.

Methods: This post hoc analysis used data from three randomized, placebo-controlled trials including patients with r-axSpA from COAST-V [biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve] and COAST-W (tumor necrosis factor inhibitor-experienced) and patients with nr-axSpA from COAST-X (bDMARD-naïve). Patients received ixekizumab (80 mg every 2 or 4 weeks) or placebo through Week 16 and ixekizumab to Week 52. Assessments included the Assessment in SpondyloArthritis international Society 40% improvement (ASAS40) and Axial Spondyloarthritis Disease Activity Score (ASDAS) low disease activity [LDA (< 2.1)] and Bath Ankylosing Spondylitis Disease Activity Index 50% improvement (BASDAI50) response rates through Week 52 and change from baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) at Week 16.

Results: Fewer patients treated with ixekizumab (pooled dosing) had shorter versus longer symptom duration [n = 33 vs. n = 306 (r-axSpA); n = 73 vs. n = 111 (nr-axSpA)]. Ixekizumab-treated patients with shorter versus longer symptom duration had numerically higher response rates at Week 16/Week 52 for ASAS40 [51.5/60.6 vs. 36.9/40.5 (r-axSpA); 42.5/54.8 vs. 36.0/41.4 (nr-axSpA)], ASDAS LDA [39.4/48.5 vs. 27.5/35.6 (r-axSpA); 32.9/49.3 vs. 27.9/36.9 (nr-axSpA)], and BASDAI50 [42.4/54.5 vs. 31.4/36.6 (r-axSpA); 38.4/49.3 vs. 27.9/34.2 (nr-axSpA)]. However, relative risk ratios at Week 16 did not significantly favor the shorter duration subgroup. Findings were comparable for SF-36 PCS at Week 16. The present findings should be interpreted in the context of small numbers of patients in some shorter duration subgroups.

Conclusion: Ixekizumab was shown to be efficacious in both patients with shorter or longer symptom duration and in r-axSpA or nr-axSpA.

Keywords

Humans, Antibodies, Monoclonal, Humanized, Male, Adult, Quality of Life, Female, Axial Spondyloarthritis, Middle Aged, Antirheumatic Agents, Time Factors, Treatment Outcome, Double-Blind Method, Severity of Illness Index

Comments

Trial registration: ClinicalTrials.gov Identifiers, NCT02696785; NCT02696798; NCT02757352.

Published Open-Access

yes

Recommended Citation

Navarro-Compán, Victoria; Reveille, John D; Rahman, Proton; et al., "Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration" (2025). Faculty, Staff and Student Publications. 3692.
https://digitalcommons.library.tmc.edu/uthmed_docs/3692